Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

61. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Kansal AR, Sharma M (...) , Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of dabigatran versus rivaroxaban as anticoagulation therapies for prevention

NHS Economic Evaluation Database.2012

62. Rivaroxaban in patients with a recent acute coronary syndrome.

Rivaroxaban in patients with a recent acute coronary syndrome. 22077192 2012 01 05 2012 01 12 2015 11 19 1533-4406 366 1 2012 Jan 05 The New England journal of medicine N. Engl. J. Med. Rivaroxaban in patients with a recent acute coronary syndrome. 9-19 10.1056/NEJMoa1112277 Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve (...) cardiovascular outcomes in patients with a recent acute coronary syndrome. In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban significantly reduced the primary efficacy end point

NEJM2012

63. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 22449293 2012 04 05 2012 04 12 2015 11 19 1533-4406 366 14 2012 Apr 05 The New England journal of medicine N. Engl. J. Med. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 1287-97 10.1056/NEJMoa1113572 A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need (...) for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic

NEJM2012

64. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

RxFiles2012

65. What role can dabigatran,rivaroxaban and apixaban play in the future?

What role can dabigatran,rivaroxaban and apixaban play in the future? Vol 19. DTB: Vol 19, No 3. May - July 2011 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB: Vol 19, No 3. May - July 2011 DTB: Vol 19, No 3. May - July 2011 Content tools Share it What role can dabigatran, rivaroxaban and apixaban play in the future? Dabigatran, rivaroxaban and apixaban have shown to be non inferior to warfarin. However these drugs might

Drug and Therapeutics Bulletin of Navarre (Spain)2011

66. Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations.

Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 21992495 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Oct 27;365(17):1557-9. doi: 10.1056/NEJMp1110639. Epub 2011 Oct 5. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. 1 , . 1 Department of Biostatistics, University of Washington, Seattle, USA. PMID: 21992495 DOI: [Indexed

NEJM2011

67. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

Health Technology Assessment (HTA) Database.2011

68. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Loke YK, Kwok CS CRD summary The authors concluded that oral anticoagulant rivaroxaban may be more effective than dabigatran for prevention (...) of venous thromboembolism after elective orthopaedic surgery, but that it might slightly increase the risk of haemorrhage. These conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To compare the efficacy and safety of dabigatran and rivaroxaban (oral anticoagulants) for prevention of venous thromboembolism after elective orthopaedic surgery. Searching PubMed (1950 onwards) and EMBASE (1980 onwards) were searched in May 2009. Search terms were reported

DARE.2011

69. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

Health Technology Assessment (HTA) Database.2011

70. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong (...) L, Lees M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after surgery in patients undergoing total hip or knee

NHS Economic Evaluation Database.2011

71. Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications

Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed

Evidence-Based Medicine (Requires free registration)2011

72. Xarelto (rivaroxaban)

Xarelto (rivaroxaban) Drug Approval Package: Xarelto (rivaroxaban) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Xarelto (rivaroxaban) 10 mg immediate release Tablets Company: Johnson and Johnson Pharmaceutical Research and Development, LLC Application No.: 022406 Approval Date: 07/01/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

73. Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 Company: Janssen Pharmaceuticals Application No.: 202439 Approval Date: 11/04/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

74. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 21830957 2011 09 08 2011 09 16 2016 03 07 1533-4406 365 10 2011 Sep 08 The New England journal of medicine N. Engl. J. Med. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 883-91 10.1056/NEJMoa1009638 The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent (...) and predictable anticoagulation than warfarin. In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. In the primary analysis, the primary end point occurred in 188

NEJM2011

75. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Cao YB, Zhang JD, Shen H, Jiang YY CRD summary This generally well-conducted (...) review concluded that rivaroxaban was more effective than the recommended dose of enoxaparin and had a similar safety profile for thromboprophylaxis after hip and knee joint replacement surgery. High levels of variation limit the reliability of the main efficacy analyses, so caution is warranted when interpreting the authors’ conclusions. Authors' objectives To compare the efficacy and safety of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty. Searching

DARE.2010

76. Oral rivaroxaban for symptomatic venous thromboembolism.

Oral rivaroxaban for symptomatic venous thromboembolism. 21128814 2010 12 23 2010 12 30 2015 11 19 1533-4406 363 26 2010 Dec 23 The New England journal of medicine N. Engl. J. Med. Oral rivaroxaban for symptomatic venous thromboembolism. 2499-510 10.1056/NEJMoa1007903 Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. We conducted an open-label (...) , randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who

NEJM2010

77. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement 19407299 2009 05 01 2009 06 01 2015 11 19 2044-5377 91 5 2009 May The Journal of bone and joint surgery. British volume J Bone Joint Surg Br Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. 636-44 10.1302/0301-620X.91B5.21691 A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared (...) with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme). A pooled analysis of data from these studies (n = 9581) showed that rivaroxaban was more effective than enoxaparin in reducing the incidence of the composite of symptomatic venous thromboembolism and all-cause mortality at two weeks (0.4% vs 0.8%, respectively, odds ratio 0.44; 95% confidence interval 0.23 to 0.79; p = 0.005

EvidenceUpdates2009

78. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 170. 2009 Authors' conclusions Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip

Health Technology Assessment (HTA) Database.2009

79. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170) Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | Guidance and guidelines | NICE Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Technology appraisal guidance [TA170] Published date: 22 April 2009 Share Guidance wherever possible. Explore Guidance app

National Institute for Health and Clinical Excellence - Technology Appraisals2009

80. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement application/octet-stream

Monash Health Evidence Reviews2009